Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson ERLEADA (apalutamide) by Year
ERLEADA (apalutamide) — Worldwide reported growth YoY (%) (%)
Johnson & Johnson ERLEADA (apalutamide): 19.2% in FY2025, down 6.4 pts from a year earlier.
Latest, FY2025
19.2%
Period ended Dec 28, 2025
Change on a year earlier
-6.4 pts
25.6% in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| WW | 3,574 | 2,999 | 19.2 | 17.2 | 2.0”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ERLEADA (apalutamide) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 19.2% | -6.4 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 25.6% | -1.3 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | 26.9% | -18.8 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | 45.7% | -24.3 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | 70.0% | – | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson ERLEADA (apalutamide) (%), annual FY2021–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-erleada-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.